ClinicalTrials.gg

Cytomegalovirus Infections clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 370 studies for Cytomegalovirus Infections across more than 10 countries. 57 are recruiting or about to start. 274 of them are mainly about Cytomegalovirus Infections (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-09. Counting its narrower condition Cytomegalovirus Retinitis too: 402 studies, 58 open.

Status

Completed
228
Status unknown
35
Recruiting
35
Terminated
25
Not yet recruiting
16
Withdrawn
12

Phase

Phase 2
79
Phase 1
71
Phase 3
46
Phase 4
36
Early Phase 1
2

Where

United States
178
France
48
Spain
26
United Kingdom
26
China
23
Italy
18

Who develops what

Add Cytomegalovirus Infections to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 2 programs from 2 companies, 2 with this as their studies’ main aim; 0 with a live phase 3 study; 1 primary completion in the next 12 months.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
GanciclovirRecent, limited
Evidence
  • NCT06853184 · amivas inc · Phase 2 · live · comparator · “Ganciclovir (GCV)” · registered Feb 2025
  • NCT00497796 · Takeda · Phase 3 · comparator · “ganciclovir” · registered Jul 2007
Hoffmann-La Roche68% of its industry studiesUS: off-patent, 5 generics marketed11 study

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 2 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (1)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 4 Jun 2027 est.LB-DTK-MV · LucasBio · Phase 2 registry mapping onlyNCT07670468 Evaluation of the Safety and Efficacy of LB-DTK-MV in Patients Diagnosed With Antiviral-Resistant CMV, BKV, or EBV Infection or Associated Diseases Following Anticancer Therapy or Allogeneic Hematopoietic Stem Cell Transplantation. — primary endpoint: CMV viral load · 27 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Cytomegalovirus Infections studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here mTOR inhibitors 1 open · Reverse transcriptase inhibitors 4

Coming up

20studies finish main data collection within a year2 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 35 Cytomegalovirus Infections studies recruiting now, 20 (57%) set no upper age limit and 13 (37%) stop at 75 or younger. 19 (54%) take children under 18. 1 (3%) are for women only and 0 (0%) for men only; 2 (6%) take healthy volunteers.

Recruiting studies that take each age, of 35
AgeWomenMen
1015 (43%)15 (43%)
1830 (86%)29 (83%)
3026 (74%)25 (71%)
4025 (71%)24 (69%)
5025 (71%)24 (69%)
6525 (71%)24 (69%)
7522 (63%)21 (60%)
8521 (60%)20 (57%)

Across all 370 studies, recruiting or not: 40% stop at 75 or younger and 34% at 65; 46% take children; 9% are for women only and 3% for men only; 17% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Cytomegalovirus Infections studies take

Of 29 phase 2 interventional studies under Cytomegalovirus Infections, half reached primary completion within 44 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 128 mo16–45 · 21 studies——
Phase 244 mo35–62 · 29 studies——
Interventional, no phase40 mo24–56 · 23 studies——
Observational45 mo34–61 · 30 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 19, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 370. Browse all 370 → or search them.